Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Interleukin-1 beta inhibition with canakinumab and reducing lung cancer-subset analysis of the canakinumab anti-inflammatory thrombosis outcome study trial (CANTOS).

Literature DB >> 30370085

Interleukin-1 beta inhibition with canakinumab and reducing lung cancer-subset analysis of the canakinumab anti-inflammatory thrombosis outcome study trial (CANTOS).

David Crossman¹, Alexander M K Rothman².

Abstract

Entities: Chemical

Year: 2018 PMID： 30370085 PMCID： PMC6186576 DOI： 10.21037/jtd.2018.07.50

Source DB: PubMed Journal: J Thorac Dis ISSN： 2072-1439 Impact factor: 3.005

× No keyword cloud information.

19 in total

1. Three polymorphisms in interleukin-1β gene and risk for breast cancer: a meta-analysis.

Authors: Xiaoan Liu; Zhanwei Wang; Jinhua Yu; Gang Lei; Shui Wang
Journal: Breast Cancer Res Treat Date: 2010-05-01 Impact factor: 4.872

Review 2. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions.

Authors: Ron N Apte; Shahar Dotan; Moshe Elkabets; Malka R White; Eli Reich; Yaron Carmi; Xiaping Song; Tatyana Dvozkin; Yakov Krelin; Elena Voronov
Journal: Cancer Metastasis Rev Date: 2006-09 Impact factor: 9.264

3. Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).

Authors: S Ramalingam; J Crawford; A Chang; C Manegold; R Perez-Soler; J-Y Douillard; N Thatcher; F Barlesi; T Owonikoko; Y Wang; P Pultar; J Zhu; R Malik; G Giaccone
Journal: Ann Oncol Date: 2013-09-19 Impact factor: 32.976

Review 4. Aspirin and Cancer.

Authors: Paola Patrignani; Carlo Patrono
Journal: J Am Coll Cardiol Date: 2016-08-30 Impact factor: 24.094

5. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer.

Authors: G Giaccone; L A Bazhenova; J Nemunaitis; M Tan; E Juhász; R Ramlau; M M van den Heuvel; R Lal; G H Kloecker; K D Eaton; Q Chu; D J Dunlop; M Jain; E B Garon; C S Davis; E Carrier; S C Moses; D L Shawler; H Fakhrai
Journal: Eur J Cancer Date: 2015-08-14 Impact factor: 9.162

6. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.

Authors: Paul M Ridker; Jean G MacFadyen; Tom Thuren; Brendan M Everett; Peter Libby; Robert J Glynn
Journal: Lancet Date: 2017-08-27 Impact factor: 79.321

7. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.

Authors: M Reck; I Bondarenko; A Luft; P Serwatowski; F Barlesi; R Chacko; M Sebastian; H Lu; J-M Cuillerot; T J Lynch
Journal: Ann Oncol Date: 2012-08-02 Impact factor: 32.976

Interleukin-1 beta inhibition with canakinumab and reducing lung cancer-subset analysis of the canakinumab anti-inflammatory thrombosis outcome study trial (CANTOS).

1. Three polymorphisms in interleukin-1β gene and risk for breast cancer: a meta-analysis.

Review 2. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions.

3. Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).

Review 4. Aspirin and Cancer.

5. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer.

6. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.

7. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.

Review 8. Tumor-associated macrophages: from mechanisms to therapy.

9. The Canakinumab Antiinflammatory Thrombosis Outcome Study trial-the starting gun has fired.

10. Debate: Subgroup analyses in clinical trials: fun to look at - but don't believe them!

1. Innate and adaptive immunity combined for cancer treatment.

2. Intranasal Iloprost Prevents Tumors in a Murine Lung Carcinogenesis Model.

Review 3. Cancer genome and tumor microenvironment: Reciprocal crosstalk shapes lung cancer plasticity.